Liquid biopsy and early cancer detection

What a liquid biopsy is

A traditional biopsy means removing a small piece of tissue from a suspected tumour to examine under a microscope. A liquid biopsy, by contrast, looks for signs of cancer in a sample of blood — or sometimes other body fluids. Tumours shed tiny fragments of their DNA, along with whole cancer cells and other molecules, into the bloodstream. A liquid biopsy detects and analyses these fragments. The appeal is obvious: a blood test is far less invasive than surgery or a needle into an organ, can be repeated easily over time, and can, in theory, sample signals from cancer anywhere in the body at once. That combination is why researchers are so interested in its potential.

How it works

The key ingredient is circulating tumour DNA, often shortened to ctDNA. All cells release small amounts of DNA into the blood as they die and renew, but cancer cells release DNA carrying the tell-tale mutations of the tumour. Highly sensitive laboratory techniques can pick out these cancer-specific DNA fragments from the far larger background of normal DNA, and read the mutations they carry. Some tests also capture whole circulating tumour cells. Newer "multi-cancer" tests look at chemical patterns on the DNA to guess not just whether cancer is present, but which organ it may have come from. The science relies on being able to find a very faint signal reliably amid a lot of noise.

Where it is used today

Liquid biopsy is already part of routine care in specific situations, particularly in advanced cancers. In some lung and other cancers, a blood test for ctDNA can identify a specific mutation that determines which targeted treatment is most likely to work, which is invaluable when tumour tissue is hard to reach or a fast answer is needed. Liquid biopsy is also used to monitor how a cancer is responding to treatment and to detect the emergence of resistance, sometimes earlier than scans. In these established uses, the test guides decisions in people already known to have cancer. This is the strongest and best-proven role for the technology at present.

The promise of early detection

The headline hope is different: catching cancer early, before symptoms, in people who feel well. Multi-cancer early detection tests aim to screen a single blood sample for signals from many cancer types at once, potentially spotting cancers for which no screening exists. This could be transformative, because many cancers are far more curable when found early. Large NHS-linked studies have been evaluating such tests to see whether they truly save lives, find cancers early enough to matter, and do so without excessive false alarms. The potential is genuine and substantial — but potential is not the same as proven, and early detection is where the hardest questions lie.

Limits and cautions

Enthusiasm has to be balanced with realism. Early-stage cancers shed very little DNA, so tests can miss them — a normal result does not guarantee no cancer. Tests can also raise false alarms, suggesting cancer where there is none, leading to anxiety and unnecessary scans or procedures. There is a risk of finding cancers that would never have caused harm, and of finding a signal without being able to locate its source. That is why, outside their proven uses, these tests are not yet recommended for routine screening in the UK and are being studied carefully first. Used in the right context, liquid biopsy is a powerful tool; used indiscriminately, it could cause harm as well as good.